These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19912585)

  • 1. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
    Wu Y; Zou S; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Wang JH; Champion M; Fang C; Dodd R
    Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
    Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
    Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.
    Ziemann M; Krueger S; Maier AB; Unmack A; Goerg S; Hennig H
    Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors.
    Urwijitaroon Y; Teawpatanataworn S; Kitjareontarm A
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():180-2. PubMed ID: 7886568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood.
    Seed CR; Piscitelli LM; Maine GT; Lazzarotto T; Doherty K; Stricker R; Stricker R; Iriarte B; Patel C
    Transfusion; 2009 Jan; 49(1):134-45. PubMed ID: 18954407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India.
    Kothari A; Ramachandran VG; Gupta P; Singh B; Talwar V
    J Health Popul Nutr; 2002 Dec; 20(4):348-51. PubMed ID: 12659416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of multiple donor exposure blood recipients: surveillance value and limitations for hemovigilance.
    Zou S; Wu Y; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Carrano D; Champion M; Fujii K; Fang C; Dodd R
    Transfusion; 2010 Jan; 50(1):128-38. PubMed ID: 19778336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of cytomegalovirus clinical isolate antigens by sera from cytomegalovirus-negative blood donors.
    Rahbar AR; Sundqvist VA; Wirgart BZ; Grillner L; Söderberg-Naucler C
    Transfusion; 2004 Jul; 44(7):1059-66. PubMed ID: 15225248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors.
    Furui Y; Satake M; Hoshi Y; Uchida S; Suzuki K; Tadokoro K
    Transfusion; 2013 Oct; 53(10):2190-7. PubMed ID: 23968359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
    Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients?].
    Mutlu B; Günlemez A; Türker G; Gökalp AS; Willke A
    Mikrobiyol Bul; 2008 Apr; 42(2):337-41. PubMed ID: 18697432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.
    Ziemann M; Juhl D; Görg S; Hennig H
    Transfusion; 2013 Oct; 53(10):2183-9. PubMed ID: 23581526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
    Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
    Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
    Milbradt H; Flik J; Stangel W; Heigel R
    Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections.
    Ziemann M; Heuft HG; Frank K; Kraas S; Görg S; Hennig H
    Transfusion; 2013 May; 53(5):1088-94. PubMed ID: 23320406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransfusion cytomegalovirus infections.
    Tegtmeier GE
    Arch Pathol Lab Med; 1989 Mar; 113(3):236-45. PubMed ID: 2537614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.